Illumina Inc., in collaboration with Nashville Biosciences LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, have announced the five founding new members of the Alliance for Genomic Discovery.

Here are frequently asked questions about Vanderbilt University Medical Center's Alliance for Genomic Discovery.

A Vanderbilt study of genetic risks for cognitive impairment later in life uses data from 32,426 research participants ages 60 and older to elaborate these risks across sex and across the intersection of sex and race.

A recent Vanderbilt study is one of the first to use statistical and population-based methods to understand comorbidities associated with developmental language disorder at a population level.

Genetic mosaicism — when the body’s cells do not all have the same genetic makeup — could generate variants previously thought to be spontaneous in genetic disease, and detecting parental mosaicism could clarify recurrence risk for future children.

A Vanderbilt analysis of population genetic testing concludes with a recommendation to U.S. health policymakers to adopt routine testing of adults ages 40 and under for three genetic conditions posing high risk of life-threatening illness.

Polygenic risk scores — scores that reflect the influence of common genetic variants — could be used to predict the likelihood of developing chronic overlapping pain conditions and guide biomarker and targeted prevention efforts.